Clinical Impact of New Rheumatoid Arthritis Findings From EULAR 2020*

Download All
June 3-6, 2020; Virtual Meeting
Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from EULAR 2020.

Rheumatoid Arthritis Highlights From EULAR 2020

Capsule Summary Slidesets

In this descriptive analysis, upadacitinib 30 mg was associated with a higher rate of serious and opportunistic infections, including herpes zoster, compared with the 15 mg dose.

Released: July 7, 2020

In RA patients with high disease activity by DAS28, observed absolute risk of developing a VTE event within 1 year of rheumatologist visit was 1 in 100.

Released: August 13, 2020

Overall, 7% of adults self-reported biologic-associated fatigue. Compared with patients not reporting fatigue, they were younger and more frequently smoked, were more likely to have Crohn disease, and used infliximab, rituximab, or vedolizumab.

Released: August 13, 2020

Numerically lower probability of discontinuation with JAK inhibitors vs TNF inhibitors in adjusted analysis of 25,521 patients with rheumatoid arthritis.

Released: July 1, 2020

Analysis of individual case safety reports in worldwide pharmacovigilance database examines thromboembolic events with tofacitinib and baricitinib.

Released: July 1, 2020

Among patients receiving DMARDs for RA, risk of herpes zoster was significantly higher with JAK inhibitors, monoclonal TNF inhibitor antibodies, B-cell­–targeted therapy, T-cell costimulation modulation, or IL-6 inhibition.

Released: July 1, 2020

At 12 weeks, change in DAS28-CRP with upadacitinib was noninferior to (primary endpoint) and also superior to (secondary endpoint) abatacept. Upadacitinib was also associated with superior rate of clinical remission (DAS28-CRP < 2.6).

Released: August 17, 2020

Efficacy of add-on therapy with JAK1 inhibitor filgotinib sustained through Week 52 with no new safety signals in patients with rheumatoid arthritis and inadequate response to methotrexate.

Released: July 13, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings